Armata Pharmaceuticals (ARMP) Projected to Post Earnings on Tuesday

Key Points

• Armata Pharmaceuticals (ARMP) is set to announce its quarterly earnings before the market opens on Tuesday, August 12th, with expected losses of ($0.39) per share and revenue of $1.38 million.
• The company's stock is currently down 3.1%, trading at $2.63, with a market cap of $95 million and a price-to-earnings ratio of -3.16.
• HC Wainwright has raised Armata Pharmaceuticals' price target from $7.00 to $9.00 and maintains a "buy" rating, providing optimism for investors.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Armata Pharmaceuticals to post earnings of ($0.39) per share and revenue of $1.38 million for the quarter.

Armata Pharmaceuticals Stock Down 8.9%

Armata Pharmaceuticals stock traded down $0.23 during mid-day trading on Thursday, hitting $2.36. The company had a trading volume of 7,006 shares, compared to its average volume of 12,265. Armata Pharmaceuticals has a 12 month low of $0.90 and a 12 month high of $2.96. The company has a market capitalization of $85.41 million, a P/E ratio of -2.84 and a beta of 0.99. The business has a 50 day simple moving average of $2.16.

Analysts Set New Price Targets

Separately, HC Wainwright upped their price target on shares of Armata Pharmaceuticals from $7.00 to $9.00 and gave the stock a "buy" rating in a research note on Monday, May 19th.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.